Biotech & Longevity · Tuesday, 27 October 2026

01 Briefing what happened

Nigeria flies its only Ebola patient to a hospital in Geneva, as Africa's disease agency sends scientists to learn how she caught a rare strain without going to Congo

Nigeria's Ebola patient was flown to Switzerland on Monday, and Africa CDC is sending a team led by a scientist who helped discover Ebola to find out whether the virus is spreading unseen in Uganda.

people Nigeria is watching after contact with the patient

the first 44 were health workers; nine more include her family and household staff [4]

~10,000

Ebola cases in Congo since May, its deadliest outbreak

Ituri province, where it is worst, has had 3,298 deaths [3]

$6.7m

Nigeria's emergency money for the response, 10 billion naira

for laboratory tests, protective gear and health workers [6]

countries the outbreak has reached: Congo, Uganda, Kenya and Nigeria

the widest spread of any Ebola outbreak in Africa so far [1]

The lead story — what happened

Nigeria flew its only Ebola patient from Abuja, its capital, to Switzerland on Monday morning, health minister Muhammad Ali Pate said. [1][4]
She is a 42-year-old woman born in Uganda and married to a Swiss diplomat. She is being treated at Geneva University Hospitals. [4][5]
Pate said she was stable, awake and talking. He added that this does not mean she can no longer pass on the virus. [1][4]
Her husband has no symptoms. He flew on the same plane and is in isolation at University Hospital Zurich. [1][5]
Africa CDC, the African Union's disease agency, is sending leading Ebola scientists to Nigeria to find out how she was infected, its head Jean Kaseya told Reuters. [2]
The team will be led by Jean-Jacques Muyembe, the Congolese scientist who helped discover Ebola. [2]
Kaseya said her travel papers show she never visited Congo, where this outbreak began in May. She had spent two weeks on holiday in Uganda. [1][2]
If she caught it in Uganda, the virus may be passing between people there without anyone knowing. [1] Uganda's last recorded case was on 21 June. [3]
Nigeria now lists 53 people who were in contact with her, nine more than its first count. Most are health workers. [4]
Nigeria's government released 10 billion naira, about $6.7 million, in emergency money for tests, protective gear and health workers. [6]
At the land border with Benin, an AFP reporter saw health forms that asked about fever but not about Ebola, and no temperature checks. [4]
The outbreak is caused by Bundibugyo, a rare kind of Ebola with no approved vaccine or treatment. It has now reached four countries. [1][2]
On Friday, gene tests found her virus closely related to the one that infected Kenya's first patient. Kaseya said this does not mean one of them infected the other. [2]

~10,000Congo

20Uganda

9Kenya

1Nigeria

Ebola cases so far in each country this outbreak has reached. Almost all of them are in Congo, where it began in May.

Who is involved

Muhammad Ali Pate

Nigeria's health minister; he approved the flight and reported her condition
Jean Kaseya

head of Africa CDC, the African Union's disease agency; he is sending the scientists
Jean-Jacques Muyembe

a Congolese scientist who helped discover Ebola; he will lead the team
Uganda's health ministry

Uganda's government health department; it says she had no symptoms when she left and is tracing her movements

How it unfolded

3 Oct She flies through Entebbe airport in Uganda, about 40 minutes apart from Kenya's first patient [2]
20 Oct Nigeria announces her as its first Ebola case in more than a decade [4][1]
22 Oct Switzerland says she was infected in Uganda, not in Congo [8]
23 Oct Gene tests show her virus is closely related to the Kenyan patient's [2]
26 Oct She is flown to Geneva, and Africa CDC sends scientists to Nigeria [1][2][5]

Where this points

The next fact to watch is where Muyembe's team says she caught the virus: if it was Uganda, declared free of Ebola in August, the virus has been passing between people there unseen. [2][3]

Signals on this beat

The bar and the word are our reading of how hard each one is pushing, and the arrow is where it is heading.

Ebola spreading past Congo High↑

Nigeria flew its only patient to Switzerland and is watching 53 of her contacts. [4] In Beni, a city in eastern Congo, rumours of poison and evil spirits keep some sick families away from treatment. [9] Ituri, the Congolese province where the outbreak is worst, has had 3,298 Ebola deaths. [3]

Best sellers losing patents Building↑

Merck needs new sellers before Keytruda, its biggest cancer drug, loses patent protection in 2028. [10] Incyte's best seller, Jakafi, loses its protection in 2028 too. [14] Bayer won approval in China for a new stroke pill as some of its biggest medicines face cheaper copies. [19]

Cancer drugs chasing a rival High↑

Analysts set Genmab's new ovarian cancer drug against AbbVie's Elahere, which is already on sale. [11] BioNTech said its breast cancer drug would add little next to Enhertu, a drug already in use. [12] Incyte's research chief called its pancreatic cancer drug 'neck and neck' with Revolution Medicines' rival. [14]

Fixed money for medicines Building→

Israel has 650 million shekels to add new treatments for 2027, the same sum as every year since 2023. [21] Pakistan ordered a review of the formula that sets its medicine prices. [22] Drugmakers there say prices held still for years can force them to stop making a medicine. [22]

The rest of the day

17 more stories on this beat.

Each with its own sources. None of these is a link to the story above.

02
Merck's cancer drug cuts deaths by a third

A drug from Merck, a big US drugmaker, and Kelun-Biotech, a Chinese company, cut the risk of death by about a third in advanced endometrial cancer. [10] Endometrial cancer, which starts in the lining of the womb, is a common cancer in women. [10] The result came from a final-stage trial presented on Monday at a cancer meeting in Madrid. [10] The drug, sacituzumab tirumotecan or sac-TMT, is a targeted chemotherapy already approved in China. [10]

Why it matters — Merck is running 18 final-stage trials of sac-TMT around the world, 10 of them in women's cancers, to win approval outside China. [10] It needs new sellers before Keytruda, its best-selling drug, loses patent protection in 2028. [10]
03
Genmab's ovarian cancer drug wins its final trial

Genmab, a Danish drugmaker, said its drug Rina-S passed its first final-stage trial, in 582 women with ovarian cancer that no longer responds to platinum chemotherapy. [11] Against the usual chemotherapy, it cut the risk of the cancer growing or death by 71%. [11] It also cut the risk of death by 57%. [11] Genmab announced it on Friday 23 October and has shared only top-line figures so far. [11] At ESMO it also showed a second drug, petosemtamab, given with Keytruda, shrinking tumours in 63% of 43 head and neck cancer patients. [11]

Why it matters — Analysts at William Blair said the results look strong next to AbbVie's rival Elahere and may reach more patients. [11] Last year AbbVie went to court, accusing Genmab of ignoring stolen trade secrets when it bought Rina-S. Genmab denies it. [11]
04
BioNTech's breast cancer drug helps only a little

BioNTech, the German company behind a Covid vaccine, said on Monday its breast cancer drug met its main goal in a final trial but helped only modestly. [12][13] The drug, trastuzumab pamirtecan, is an antibody that carries a cell-killing drug to cancer cells. [12] It slowed HER2-low breast cancer, a kind with small amounts of a protein called HER2, better than chemotherapy. [12] More patients got lung inflammation than in earlier tests, and a small share had severe or fatal events. [12][13]

Why it matters — The companies said the benefit would be limited because Enhertu, from AstraZeneca and Daiichi Sankyo, already treats this cancer. [12] BioNTech had reported two other trial setbacks before this one, including a missed goal for its mRNA cancer vaccine BNT113 this month. [12][13]
05
Incyte's pancreatic cancer drug shrinks most tumours

Incyte, a US drugmaker, showed early results at ESMO for INCB161734, a drug aimed at one faulty form of a gene called KRAS, known as G12D. [14][15] Given with the chemotherapy mix FOLFIRINOX, it shrank tumours in 81% of 28 patients with pancreatic cancer. [14] With a different chemotherapy, the figure was 58% of 26 patients. [14] Diarrhoea hit 68% of patients and nausea 64%. [14] A final trial has started, with results expected in 2028. [14]

With FOLFIRINOX81%
With gemcitabine mix58%
Share of patients whose tumours shrank on Incyte's drug, by the chemotherapy given with it.

Why it matters — Incyte's research chief said the drug is 'neck and neck' with one from Revolution Medicines, which already sells a pancreatic cancer pill. [14] Incyte needs new drugs before its best seller, Jakafi, loses patent protection in 2028. [14]
06
Tango cuts staff to pay for one drug

Tango Therapeutics, a US biotech, said it will cut about 14% of its staff, mostly researchers looking for new drug targets. [16] It will focus its money on drugs such as vopimetostat, given with Revolution Medicines' pill Rasonque for pancreatic cancer. [16] At ESMO, tumours shrank in 82% of 22 patients, down from 92% of 12 at a count in May. [16] Tango's shares fell 16.4% on Friday. [16]

May, 12 patients92%
August, 22 patients82%
Share of patients whose pancreatic tumours shrank on Tango's pair of drugs, at two counts of the same trial.

Why it matters — Tango plans a final trial in the first half of next year but has no deal yet with Revolution Medicines to supply Rasonque for it. [16] Its chief executive said other options are being looked at. [16]
07
J&J's prostate cancer pill moves to a final trial

Johnson & Johnson, a big US drugmaker, showed early results at ESMO for JNJ-6143, a daily pill for advanced prostate cancer. [17][18] At the 50mg dose, 77% of patients saw their PSA, a blood marker of the cancer, fall by at least half. [17][18] The pill grips a protein found on the cancer and a protein the cell needs to live, so the cell dies. [18] It came with J&J's $3.05 billion purchase of Halda Therapeutics last year. [17]

Why it matters — A final trial is set to start this week, Fierce Biotech reported on Sunday. [18] Only those later trials can show whether men on the pill live longer. [18]
08
China approves Bayer's stroke pill

China's drug regulator said on Monday it had approved asundexian, a blood thinner from Bayer, the German drugmaker. [31][19] It will be sold as Sunharbo, to lower the risk of another stroke in adults who have already had one. [19] A stroke happens when blood stops reaching part of the brain, often because of a clot, and a blood thinner makes clots less likely to form.

Why it matters — Patients in China who have had a stroke get a new pill aimed at stopping a second one. [19] For Bayer, it is a new seller as some of its biggest medicines lose sales to cheaper copies. [19]
09
Corxel plans a share listing for its weight-loss pill

Corxel Pharmaceuticals, a drug startup, said on Monday it will list on the stock market by merging with a shell company already listed there. [20] With $300 million from private investors, the money will take CX11, a weight-loss pill licensed from China's Vincentage Pharma, into a final trial. [20] In a US mid-stage trial, people on CX11 lost up to 11.5% of their weight in 36 weeks. [20] A late-stage trial in China, run by Vincentage, was positive in May. [20]

31 of 100
US adults who are overweight but not obese
About 31 in every 100 US adults fit the group Corxel is aiming its pill at, by one NIH estimate.

Why it matters — An international final trial could start in early 2027. [20] CX11 trails pills from Eli Lilly and Novo Nordisk, so Corxel is aiming it at people who are overweight but not obese, about 31% of US adults. [20]
10
Rumours keep Ebola patients from care in Congo

In Beni, a city in eastern Congo, rumours are keeping some sick families away from Ebola treatment centres, Africanews reported. [9] Healers and a pastor told Zawadi Kavira Musubao's family that their illness came from poison or evil spirits. [9] She lost four relatives, including her son. [9] Her brother, a village chief, then took more than a dozen relatives to the treatment centre. [9] Musubao says he saved her life. [9] Congo's health ministry counts more than 9,800 cases and 4,700 deaths since May. [9]

Why it matters — Her brother had to argue against the belief that people who go to a treatment centre never come out alive, telling relatives that some recover. [9] Communities long neglected by Congo's government are wary of its officials, and several treatment centres and health workers have been attacked. [9]
11
Israel's yearly sum for new drugs stays flat

Israel's health basket committee, which picks the drugs and treatments the state pays for, began work on Monday on its list for 2027. [21] It has 650 million shekels, about $211 million, to add new treatments. [21] That is the same sum added every year since 2023, while the population ages and new drugs arrive. [21] On the table are new cancer drugs, a meningitis vaccine called Bexsero for children, and wider access to diabetes pills. [21]

2023650 m shekels
2024650 m shekels
2025650 m shekels
2026650 m shekels
2027650 m shekels
The money Israel adds each year for new treatments in its state-paid list. It has not changed since 2023.

Why it matters — The panel was appointed late, so new drugs may not be added until early next year. [21] Patients who need them before then may have to pay a lot themselves. [21]
12
Pakistan reviews how it prices medicines

Pakistan's government ordered a review of the formula that sets medicine prices, and said no price may rise without good reason. [22] Ahad Cheema, the economic affairs minister, gave the order on Monday at a meeting of DRAP, Pakistan's drug regulator. [22] He suggested DRAP pay for international drug-price databases, to check prices against other countries. [22] Officials told the meeting there is enough of the flu vaccine the WHO recommends on sale. [22]

Why it matters — Drugmakers say prices held still for years, while imported ingredients cost more, can force them to stop making a medicine. [22] They want regular rises tied to costs written into the new formula. [22]
13
US vaccine-injury centre will study more than vaccines

A new centre at the NIH, the US government's medical research agency, has a wider job than its launch suggested, STAT reported. [23] Health secretary Robert F. Kennedy Jr. announced it this month as a centre for people hurt by vaccines. [23] It is a study inside the NIH's infectious disease institute that will enrol several hundred people with vaccine injuries or lasting symptoms after an infection, such as long Covid. [23] It will not treat patients. [23]

Why it matters — Its aim, an official said, is to learn why some immune systems react more strongly than others and to make vaccines safer. [23] Even people worried by Kennedy's doubts about vaccines have praised its director. [23]
14
An AI company says its models can run lab machines

Anthropic, the company that makes the Claude AI, said in papers filed in the US on Monday that it plans to grow in the life sciences. [24][25] It said Claude can now operate lab equipment such as microscopes, liquid handlers and robot arms, using a standard it began with Janelia, a research campus of the Howard Hughes Medical Institute. [24] Anthropic runs its own molecular biology lab, which recently found a stretch of DNA a little like CRISPR, a gene-editing tool. [25] The filing does not say how much it spends on this work. [24]

Why it matters — The filing also warns that its safeguards against the AI being used to make biological or chemical weapons are incomplete and have been got around before. [25] It says lab work brings new risks for the company, such as workplace injuries and pollution. [25]
15
Video shows baby monkeys in a toxin study

Peta, an animal-rights group, released video on Monday of experiments on newborn monkeys at the University of Washington's primate research centre. [26] Researchers gave 32 pregnant macaques daily doses of domoic acid, a toxin from sea algae that builds up in shellfish. [26] They took 28 babies from their mothers to test whether the toxin had harmed their brains. [26] The project ran from 2014 to 2020 with more than $4.2 million from the NIH. [26]

Why it matters — The centre says the work helps explain how the toxin may affect learning, but there is no clear sign it changed health advice. [26] More than 106,000 monkeys were held in US labs in 2025, up 1.5% on the year before. [26]
16
Six genes may predict leukaemia survival

Scientists at the Centre for Genomic Regulation (CRG), a research institute, found six genes whose activity helps predict how long people with acute myeloid leukaemia live. [27] AML is a blood cancer whose outcome varies widely from one patient to the next. [27] The team moved between experiments in mice and patient records, keeping genes that behaved the same way in both. [27] The work was published in the journal Science Advances. [27]

Why it matters — Patients already give a bone marrow sample, and measuring six genes is simpler and cheaper than reading a full genetic profile. [27] It is a step toward a test, not yet a test doctors can order. [27]
17
WuXi AppTec raises its sales forecast again

WuXi AppTec, a Chinese company that drugmakers pay to research and make their medicines, raised its forecast for this year's sales again on Monday. [28][30] Its profit in the first nine months of 2026 rose 62.4% to 19.16 billion yuan, about $2.87 billion, from 11.80 billion a year earlier. [28] Its revenue rose 38.6% over the same months. [28] It works for clients in more than 30 countries. [30]

Why it matters — WuXi said the rise came from more of its customers' medicines succeeding. [30] Its figures for the third quarter have not yet been checked by auditors. [30]
18
A toad-venom nose spray eases hard depression

A nose spray of mebufotenin, a psychedelic drug first found in the venom of the Sonoran Desert toad, eased depression in a mid-stage trial published in JAMA on Monday. [29] Its 193 patients in Australia, Europe and the US had already tried two to five antidepressants without success. [29] Each got one dose, and most were ready to go home within about two hours. [29] Benefits began about two days later and lasted at least eight weeks, though one patient had two severe panic attacks. [29]

Why it matters — The 8mg dose now moves to a final trial against existing treatments. [29] Chittaranjan Andrade, a psychiatrist outside the trial, wrote that the average patient got only about 30% better, and fewer recovered than usually do on ketamine. [29]

02 Lesson why it matters

Why matching virus genes show two cases are linked but not who passed it on

A virus picks up small copying mistakes as it spreads, so shared mistakes show two infections came from one recent source, but not the path between them.

The twist

Matching virus genes show that two cases belong to one chain of infection. They cannot show the links in that chain, so investigators still have to trace where each person went and whom they met.

How it works

A virus copies its genes each time it multiplies, and makes small mistakes
The mistakes are passed on, so each chain of infection carries its own pattern of them
Scientists read the virus's genes from each patient and compare the patterns
Nearly matching patterns mean two infections share a recent source
But the match cannot say who gave it to whom, or whether someone else sat between them

The same force, elsewhere today

Where this chain is also running, in today's other stories.

Nigeria's patient and Kenya's first patient

Their viruses were found closely related, but Kaseya says that does not mean one infected the other, so his team is checking their travel and whether a third person linked them.

Where you've seen this

Copied homework

the same spelling mistakes in two essays show they share a source, not which pupil copied whom

DNA family-tree tests

a shared stretch of DNA shows two people are related, not which grandparent joins them

Food poisoning outbreaks

matching germs from sick people point to one source, and inspectors then trace which shop sold the food

The catch

If a virus has changed little, or only a few samples have been read, unrelated cases can look alike, so a match is a lead to follow, not a finished answer.

And the whole of it

The woman in Geneva says she does not remember meeting the Kenyan man, and he has since died. If someone else carried the virus between them, nobody has named that person yet.

03 Truth what's really going on

What is really going on

Nigeria's Ebola patient is safe in a Geneva hospital, but nobody yet knows where she caught the virus. If it was in Uganda, which has recorded no case since June, the Bundibugyo strain has been passing between people there without being counted. [1][2][3]

Who gains

Genmab — A final-trial win with a 71% cut in the risk of the cancer growing sets Rina-S up against AbbVie's Elahere, already on sale. [11]
Merck and Kelun-Biotech — A one-third cut in deaths gives Merck a new cancer drug to sell before Keytruda loses patent protection in 2028. [10]
AstraZeneca and Daiichi Sankyo — BioNTech's rival to their drug Enhertu came out modest, with more lung inflammation, so Enhertu's lead in HER2-low breast cancer holds. [12][13]
Bayer — Approval in China gives it a new stroke pill to sell as some of its biggest medicines face cheaper copies. [19]
Corxel's investors — The share listing and $300 million split the weight-loss pills from the rest of the company, which its finance chief said they wanted. [20]

Who pays

Nigeria's health workers — Most of the 53 people being watched after contact with the patient are health staff. [4]
Families in eastern Congo — Healers and a pastor blamed poison and evil spirits before Musubao's brother took the family for treatment, and she lost four relatives, including her son. [9]
Tango's researchers — About 14% of the company's staff will go, mostly from the team looking for new drug targets. [16]
Patients waiting in Israel — The panel was appointed late, so new drugs may not be paid for until early next year, and patients may pay themselves until then. [21]
Patients in BioNTech's trial — More of them got lung inflammation than in earlier tests, and a small share had severe or fatal events. [12]

What nobody knows yet

Open questions from across today’s stories — ours included.

01

Where Nigeria's patient was infected.

Africa CDC says her travel papers show no visit to Congo, and she does not remember meeting Kenya's first patient. [2] Uganda says CCTV at Entebbe shows no contact between the two, and it is still tracing her movements. [7]
02

Whether any of Nigeria's 53 contacts is infected.

One suspected case in Rivers State tested negative, and the rest are still being watched. [4]
03

How many people have died in Congo.

One Reuters report gives more than 4,800 deaths and another more than 4,600. [1][2] Euronews gives more than 4,700, from Congo's figures up to 21 October. [3]
04

How large Merck's survival gain is.

The part of STAT's report we could read gives only 'one-third'; the full trial figures were not in it. [10]
05

How much BioNTech's drug helped, and whether patients live longer.

The companies gave no size for the gain, and the survival figures were not ready when the trial was analysed. [12][13]
06

What share of J&J's patients responded.

Reuters says 69% of patients with measurable tumours had a confirmed response. [17] J&J's own release, reported by Fierce Biotech, says 75%, and the two give different patient counts. [18]
07

Whether Tango can get Rasonque for its final trial.

Tango has no supply deal with Revolution Medicines, and its chief executive said some topics between the two still need settling. [16]
08

How much Anthropic spends on its life-science work.

Its filing does not give a figure or say what its biology lab is working on. [24]

04 Hope carry this

Doctors in Abuja nursed Nigeria's only Ebola patient through the worst of a strain with no approved treatment. She was awake and talking when she was flown to Geneva on Monday.

Also true today

In a trial of 582 women whose ovarian cancer no longer responded to platinum chemotherapy, Genmab's drug Rina-S cut the risk of death by 57%.
Zawadi Kavira Musubao nearly died of Ebola in Beni, in eastern Congo, and lived after her brother, a village chief, took her to a treatment centre.
A drug from Merck and Kelun-Biotech cut the risk of death by about a third in women with advanced endometrial cancer.